These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 5034697)

  • 21. Alpha-methyldopa as an adjunct to levodopa treatment of Parkinson's disease.
    Sweet RD; Lee JE; McDowell F
    Trans Am Neurol Assoc; 1971; 96():59-65. PubMed ID: 5159130
    [No Abstract]   [Full Text] [Related]  

  • 22. [L-DOPA with the decarboxylase inhibitor Ro 4-4602 in the treatment of Parkinson's disease].
    Lakke JP; Nienhuis RJ; Meyer R; Zwols F; Schut T
    Ned Tijdschr Geneeskd; 1972 Nov; 116(48):2180-4. PubMed ID: 4639072
    [No Abstract]   [Full Text] [Related]  

  • 23. [Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, benserazide-HCl, on Parkinson's disease--Part II: Pharmacokinetic study (author's transl)].
    Yokochi M; Kondo T; Hirayama K; Narabayashi H; Kuruma I
    No To Shinkei; 1979 Apr; 31(4):339-48. PubMed ID: 454549
    [No Abstract]   [Full Text] [Related]  

  • 24. L-dopa-carbidopa: combined therapy for the treatment of Parkinson's disease.
    Celesia GG; Wanamaker WM
    Dis Nerv Syst; 1976 Mar; 37(3):123-5. PubMed ID: 1253661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Indications and results of monoamine treatment in parkinsonian syndromes].
    Boudin G; Pépin B; Guillard A; Fabiani JM; Haguenau M
    Rev Neurol (Paris); 1972 Jul; 127(1):79-97. PubMed ID: 4520464
    [No Abstract]   [Full Text] [Related]  

  • 26. L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment.
    Bergonzi P; Chiurulla C; Gambi D; Mennuni G; Pinto F
    Acta Neurol Belg; 1975; 75(1):5-10. PubMed ID: 1202895
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Levodopa in treating Parkinsonism.
    O'Doherty DS
    Am Fam Physician; 1971 Nov; 4(5):95-9. PubMed ID: 5117507
    [No Abstract]   [Full Text] [Related]  

  • 28. [Comparison of the effect of L-Dopa and of an L-Dopa+decarboxylase inhibitor combination in Parkinson's disease].
    Schneider E; Fischer PA; Jacobi P; Maxion H
    Arch Psychiatr Nervenkr (1970); 1973 Mar; 217(1):95-112. PubMed ID: 4695662
    [No Abstract]   [Full Text] [Related]  

  • 29. [Therapy of Parkinson's syndrome with L-dopa only and in combination with a decarboxylase inhibitor. A comparison].
    Feise G; Paal G
    Nervenarzt; 1974 Mar; 45(3):126-32. PubMed ID: 4832035
    [No Abstract]   [Full Text] [Related]  

  • 30. [Development of studies on the treatment of parkinsonian syndromes with levodopa. II. Long-term effects of L-DOPA alone or in combination with a decarboxylase inhibitor].
    Rabadeau Dumas JL; Rondot P; Cardon P
    Therapie; 1977; 32(2):161-72. PubMed ID: 898124
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment of Parkinson's disease with L-DOPA and an association L-DOPA plus a DOPA decarboxylase inhibitor.
    Fazio C; Agnoli A; Casacchia M; Reitano M; Ruggieri S; Barba C; Volante F
    Z Neurol; 1972; 202(4):347-55. PubMed ID: 4117654
    [No Abstract]   [Full Text] [Related]  

  • 32. Modification of levodopa effect by systemic decarboxylase inhibition.
    Mars H
    Arch Neurol; 1973 Feb; 28(2):91-5. PubMed ID: 4683155
    [No Abstract]   [Full Text] [Related]  

  • 33. [Collateral effects of therapy with L-dopa in Parkinson's disease].
    Gomirato G; Perfetti CC; Ecari U
    Sist Nerv; 1970; 22(2):67-73. PubMed ID: 5504559
    [No Abstract]   [Full Text] [Related]  

  • 34. [Potentiation of L-Dopa in parkinsonism by means of an inhibitor of peripheral decarboxylation].
    Court J; Kase JC; Mena I; Palacios E
    Rev Med Chil; 1973 Jun; 101(6):452-5. PubMed ID: 4764560
    [No Abstract]   [Full Text] [Related]  

  • 35. [Abnormal movements induced by L-dopa. New therapeutic possibilities].
    Eisenring J-J ; Constantinidis J; Dick P; Yanniotis G; Tissot R
    Schweiz Med Wochenschr; 1975 Jan; 105(4):121-4. PubMed ID: 1124379
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor].
    Guillard A
    Brux Med; 1972 Oct; 52(10):673-80. PubMed ID: 4656191
    [No Abstract]   [Full Text] [Related]  

  • 37. [Action of a decarboxylase inhibitor on endogenous plasmatic DOPA, in man].
    Geissbuhler F; Constantinidis J; Gaillard JM; des Combes NJ; Tissot R
    Biomedicine; 1974 Jul; 21(7):297-8. PubMed ID: 4433662
    [No Abstract]   [Full Text] [Related]  

  • 38. [The L-dopa test in Parkinson's disease].
    Esteguy M; Bonnet AM; Kefalos J; Lhermitte F; Agid Y
    Rev Neurol (Paris); 1985; 141(5):413-5. PubMed ID: 4048732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of Parkinson's disease with levodopa and Ro 4-4602.
    Barbeau A; Gillo-Joffroy L; Mars H
    Clin Pharmacol Ther; 1971; 12(2):353-9. PubMed ID: 4930866
    [No Abstract]   [Full Text] [Related]  

  • 40. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
    Podiwinsky F; Mentasti M; Riederer P; Birkmayer W
    Wien Klin Wochenschr; 1979 May; 91(10):332-7. PubMed ID: 452602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.